ProfileGDS5678 / 1421052_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 84% 85% 83% 87% 83% 88% 84% 84% 85% 85% 86% 86% 85% 87% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.184284
GSM967853U87-EV human glioblastoma xenograft - Control 26.4013485
GSM967854U87-EV human glioblastoma xenograft - Control 36.1359483
GSM967855U87-EV human glioblastoma xenograft - Control 46.8469187
GSM967856U87-EV human glioblastoma xenograft - Control 56.0887583
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.5515988
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.0846184
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.1277384
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.2923185
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.3575285
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.4566586
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.525886
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.427285
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.7107987